These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
183 related items for PubMed ID: 9246132
1. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Meier CR, Jick H. Thorax; 1997 Jul; 52(7):612-7. PubMed ID: 9246132 [Abstract] [Full Text] [Related]
3. Case-control study of salmeterol and near-fatal attacks of asthma. Williams C, Crossland L, Finnerty J, Crane J, Holgate S, Pearce N, Beasley R. Thorax; 1998 Jan; 53(1):7-13. PubMed ID: 9577515 [Abstract] [Full Text] [Related]
4. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates CJ, Lasserson TJ, Jaeschke R. Cochrane Database Syst Rev; 2009 Jul 08; (3):CD006922. PubMed ID: 19588410 [Abstract] [Full Text] [Related]
5. Salmeterol versus theophylline in the treatment of asthma. Pollard SJ, Spector SL, Yancey SW, Cox FM, Emmett A. Ann Allergy Asthma Immunol; 1997 May 08; 78(5):457-64. PubMed ID: 9164358 [Abstract] [Full Text] [Related]
9. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Pulm Pharmacol Ther; 2009 Feb 08; 22(1):9-19. PubMed ID: 19026757 [Abstract] [Full Text] [Related]
10. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM. Clin Ther; 2007 Jul 08; 29(7):1390-402. PubMed ID: 17825690 [Abstract] [Full Text] [Related]
11. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. Mann RD, Kubota K, Pearce G, Wilton L. J Clin Epidemiol; 1996 Feb 08; 49(2):247-50. PubMed ID: 8606326 [Abstract] [Full Text] [Related]
12. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Sovani MP, Whale CI, Tattersfield AE. Drug Saf; 2004 Feb 08; 27(10):689-715. PubMed ID: 15350154 [Abstract] [Full Text] [Related]
14. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. van der Woude HJ, Winter TH, Aalbers R. Thorax; 2001 Jul 08; 56(7):529-35. PubMed ID: 11413351 [Abstract] [Full Text] [Related]
15. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Sin DD, Tu JV. Thorax; 2000 Mar 08; 55(3):194-7. PubMed ID: 10679537 [Abstract] [Full Text] [Related]
17. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. JAMA; 1994 May 11; 271(18):1412-6. PubMed ID: 7909853 [Abstract] [Full Text] [Related]
18. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Shah L, Wilson AJ, Gibson PG, Coughlan J. Cochrane Database Syst Rev; 2003 May 11; (3):CD001281. PubMed ID: 12917905 [Abstract] [Full Text] [Related]
19. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms. Prescrire Int; 2016 Nov 11; 25(176):272-277. PubMed ID: 30715829 [Abstract] [Full Text] [Related]
20. Salmeterol xinafoate in children on high dose inhaled steroids. Russell G, Williams DA, Weller P, Price JF. Ann Allergy Asthma Immunol; 1995 Nov 11; 75(5):423-8. PubMed ID: 7583864 [Abstract] [Full Text] [Related] Page: [Next] [New Search]